AbCellera Biologics Faces Challenges Amid Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2024
0mins
Source: ARS
AbCellera Biologics Inc. saw its stock drop by 8.38% as it crossed below the 5-day SMA, reflecting investor concerns following its recent earnings call insights.
The company reported a net loss of about $43 million for Q1 2026, with revenue of approximately $8 million, indicating ongoing financial pressure. CEO Carl L. Hansen highlighted the pivotal nature of 2026, with the top-line readout for ABCL635 Phase II expected in Q3, which could address a significant market need for non-hormonal menopausal vasomotor symptoms, valued over $6 billion. Despite the challenges, the company has a robust liquidity position with around $530 million in cash, allowing it to sustain its R&D efforts.
The implications of these developments suggest that while AbCellera is navigating financial difficulties, the anticipated clinical data for ABCL635 could be a turning point for the company, potentially restoring investor confidence if results are favorable.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABCL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABCL
Wall Street analysts forecast ABCL stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.440
Low
9.00
Averages
9.00
High
9.00
Current: 5.440
Low
9.00
Averages
9.00
High
9.00
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jazz Pharmaceuticals and AbCellera Sign $848M Agreement for Antibody Development
- Significant Agreement Value: Jazz Pharmaceuticals has signed an agreement with AbCellera potentially worth up to $848 million, which includes an upfront payment of $56 million and up to $792 million in milestone payments, reflecting strong confidence in next-generation antibody development.
- Focused R&D Objectives: The deal centers on leveraging AbCellera's antibody discovery engine to develop multispecific antibodies targeting gastrointestinal cancers and other solid tumors, aiming to address current treatment gaps and enhance patient options.
- Commitment to Project Advancement: AbCellera is committed to conducting discovery and early-stage research for two programs and initiating a third program within a year, ensuring continuous progress in R&D and strengthening its market competitiveness.
- Commercialization Rights Option: Jazz Pharmaceuticals holds an option for each research program, which, if exercised along with the payment of an option fee, grants exclusive worldwide commercialization rights, providing a crucial safeguard for future revenue growth.
See More
Jazz Pharmaceuticals Partners with AbCellera for Antibody Development
- Significant Financial Commitment: The collaboration between Jazz Pharmaceuticals and AbCellera includes $56 million in upfront payments and up to $792 million in potential option fees and milestone payments, reflecting strong confidence in antibody development from both parties.
- Exclusive Development Rights: Jazz has secured exclusive rights to develop and commercialize therapeutic antibodies resulting from the collaboration, which not only enhances its competitive position in oncology but also strategically expands its focus on rare diseases.
- Technological Platform Advantage: AbCellera's T-cell engager platform offers a fully integrated capability from discovery to clinical manufacturing for developing multispecific antibodies for difficult-to-treat cancers, which is expected to significantly improve outcomes compared to existing treatment options.
- Expanded R&D Plans: Under the agreement, AbCellera will conduct discovery and early-stage research for two initial programs, with a commitment to start a third program within 12 months, indicating strong potential for long-term collaboration in cancer treatment development.
See More
Jazz Pharmaceuticals Partners with AbCellera for Antibody Development
- Collaboration Agreement Details: Jazz Pharmaceuticals has entered into a collaboration with AbCellera involving $56 million in upfront payments and potential option fees and milestone payments totaling up to $792 million, indicating a significant partnership in antibody development.
- Focused Research Direction: The collaboration aims to develop next-generation T-cell engaging multispecific antibodies targeting various gastrointestinal cancers and other solid tumors, aligning with Jazz's strategic focus on rare diseases and enhancing cancer treatment outcomes.
- Technological Platform Advantage: AbCellera's T-cell engager platform offers comprehensive capabilities from discovery to clinical manufacturing, incorporating novel CD3-binding antibodies and multispecific protein engineering technology, which is expected to significantly improve existing cancer treatment efficacy.
- Future Development Potential: The agreement allows Jazz to opt for multiple research programs, which could yield substantial milestone payments and sales royalties for AbCellera, further solidifying its competitive position in the biopharmaceutical market.
See More
AbCellera Appoints New Independent Director
- New Board Member: AbCellera has appointed Dr. Victor Sandor as an independent director, bringing extensive experience as a medical oncologist and valuable strategic guidance to the company.
- Drug Development Expertise: Prior to joining AbCellera, Dr. Sandor served as Chief Medical Officer at Array BioPharma, where he successfully led the approval of Braftovi® and Mektovi®, which will aid AbCellera's progress in antibody drug development.
- Clinical Development Background: While at Incyte Corporation as Senior Vice President for Global Clinical Development, Dr. Sandor played a key role in the approval of Jakafi®, showcasing his deep expertise in clinical research and drug registration, which can support AbCellera's clinical pipeline.
- Industry Influence: Dr. Sandor currently serves on the boards of ADC Therapeutics, Kymera Therapeutics, and Prelude Therapeutics, and his addition is expected to enhance AbCellera's reputation and influence in the biotechnology sector, further advancing the company's capabilities in antibody discovery.
See More
AbCellera Biologics Q1 2026 Earnings Call Insights Highlight Key Developments
- Key Data Release in 2026: CEO Carl L. Hansen emphasized that 2026 is poised to be pivotal, with the top-line readout for ABCL635 Phase II expected in Q3, representing a potential first-in-class antibody for non-hormonal menopausal vasomotor symptoms, with a market potential exceeding $6 billion.
- Financial Performance Overview: The company reported approximately $8 million in revenue for Q1, primarily from research fees, while R&D expenses were around $47 million, leading to a net loss of about $43 million, indicating ongoing financial pressure as the focus shifts to internal pipeline development.
- Clinical Progress and Candidates: Management indicated that beyond ABCL635 and ABCL575, up to three additional clinical-stage programs are expected by the end of 2027, with plans to select a fifth development candidate in the first half of this year, showcasing the company's commitment to R&D.
- Liquidity and Funding Status: CFO Andrew Booth noted that the company has approximately $530 million in cash and equivalents, along with about $655 million in available liquidity, ensuring the ability to sustain its R&D strategy over the next three years.
See More
AbCellera Biologics to Announce Q1 Earnings on May 11
- Earnings Announcement Date: AbCellera Biologics is set to release its Q1 2023 earnings report on May 11 after market close, drawing significant attention from investors regarding its performance.
- EPS Expectations: The consensus EPS estimate stands at -$0.20, indicating challenges in profitability that may affect investor confidence and stock performance.
- Revenue Growth Forecast: Revenue is projected at $5.84 million, reflecting a 39.0% year-over-year increase, showcasing the company's growth potential in the market despite the downward revisions in EPS expectations.
- Revision Trends Analysis: Over the past three months, there have been no upward revisions in EPS estimates, with one downward revision, while revenue estimates have seen three downward adjustments, indicating a cautious market outlook on the company's future performance.
See More
Jazz Pharmaceuticals and AbCellera Sign $848M Agreement for Antibody Development
- Significant Agreement Value: Jazz Pharmaceuticals has signed an agreement with AbCellera potentially worth up to $848 million, which includes an upfront payment of $56 million and up to $792 million in milestone payments, reflecting strong confidence in next-generation antibody development.
- Focused R&D Objectives: The deal centers on leveraging AbCellera's antibody discovery engine to develop multispecific antibodies targeting gastrointestinal cancers and other solid tumors, aiming to address current treatment gaps and enhance patient options.
- Commitment to Project Advancement: AbCellera is committed to conducting discovery and early-stage research for two programs and initiating a third program within a year, ensuring continuous progress in R&D and strengthening its market competitiveness.
- Commercialization Rights Option: Jazz Pharmaceuticals holds an option for each research program, which, if exercised along with the payment of an option fee, grants exclusive worldwide commercialization rights, providing a crucial safeguard for future revenue growth.
See More
Jazz Pharmaceuticals Partners with AbCellera for Antibody Development
- Significant Financial Commitment: The collaboration between Jazz Pharmaceuticals and AbCellera includes $56 million in upfront payments and up to $792 million in potential option fees and milestone payments, reflecting strong confidence in antibody development from both parties.
- Exclusive Development Rights: Jazz has secured exclusive rights to develop and commercialize therapeutic antibodies resulting from the collaboration, which not only enhances its competitive position in oncology but also strategically expands its focus on rare diseases.
- Technological Platform Advantage: AbCellera's T-cell engager platform offers a fully integrated capability from discovery to clinical manufacturing for developing multispecific antibodies for difficult-to-treat cancers, which is expected to significantly improve outcomes compared to existing treatment options.
- Expanded R&D Plans: Under the agreement, AbCellera will conduct discovery and early-stage research for two initial programs, with a commitment to start a third program within 12 months, indicating strong potential for long-term collaboration in cancer treatment development.
See More
Jazz Pharmaceuticals Partners with AbCellera for Antibody Development
- Collaboration Agreement Details: Jazz Pharmaceuticals has entered into a collaboration with AbCellera involving $56 million in upfront payments and potential option fees and milestone payments totaling up to $792 million, indicating a significant partnership in antibody development.
- Focused Research Direction: The collaboration aims to develop next-generation T-cell engaging multispecific antibodies targeting various gastrointestinal cancers and other solid tumors, aligning with Jazz's strategic focus on rare diseases and enhancing cancer treatment outcomes.
- Technological Platform Advantage: AbCellera's T-cell engager platform offers comprehensive capabilities from discovery to clinical manufacturing, incorporating novel CD3-binding antibodies and multispecific protein engineering technology, which is expected to significantly improve existing cancer treatment efficacy.
- Future Development Potential: The agreement allows Jazz to opt for multiple research programs, which could yield substantial milestone payments and sales royalties for AbCellera, further solidifying its competitive position in the biopharmaceutical market.
See More
AbCellera Appoints New Independent Director
- New Board Member: AbCellera has appointed Dr. Victor Sandor as an independent director, bringing extensive experience as a medical oncologist and valuable strategic guidance to the company.
- Drug Development Expertise: Prior to joining AbCellera, Dr. Sandor served as Chief Medical Officer at Array BioPharma, where he successfully led the approval of Braftovi® and Mektovi®, which will aid AbCellera's progress in antibody drug development.
- Clinical Development Background: While at Incyte Corporation as Senior Vice President for Global Clinical Development, Dr. Sandor played a key role in the approval of Jakafi®, showcasing his deep expertise in clinical research and drug registration, which can support AbCellera's clinical pipeline.
- Industry Influence: Dr. Sandor currently serves on the boards of ADC Therapeutics, Kymera Therapeutics, and Prelude Therapeutics, and his addition is expected to enhance AbCellera's reputation and influence in the biotechnology sector, further advancing the company's capabilities in antibody discovery.
See More
AbCellera Biologics Q1 2026 Earnings Call Insights Highlight Key Developments
- Key Data Release in 2026: CEO Carl L. Hansen emphasized that 2026 is poised to be pivotal, with the top-line readout for ABCL635 Phase II expected in Q3, representing a potential first-in-class antibody for non-hormonal menopausal vasomotor symptoms, with a market potential exceeding $6 billion.
- Financial Performance Overview: The company reported approximately $8 million in revenue for Q1, primarily from research fees, while R&D expenses were around $47 million, leading to a net loss of about $43 million, indicating ongoing financial pressure as the focus shifts to internal pipeline development.
- Clinical Progress and Candidates: Management indicated that beyond ABCL635 and ABCL575, up to three additional clinical-stage programs are expected by the end of 2027, with plans to select a fifth development candidate in the first half of this year, showcasing the company's commitment to R&D.
- Liquidity and Funding Status: CFO Andrew Booth noted that the company has approximately $530 million in cash and equivalents, along with about $655 million in available liquidity, ensuring the ability to sustain its R&D strategy over the next three years.
See More
AbCellera Biologics to Announce Q1 Earnings on May 11
- Earnings Announcement Date: AbCellera Biologics is set to release its Q1 2023 earnings report on May 11 after market close, drawing significant attention from investors regarding its performance.
- EPS Expectations: The consensus EPS estimate stands at -$0.20, indicating challenges in profitability that may affect investor confidence and stock performance.
- Revenue Growth Forecast: Revenue is projected at $5.84 million, reflecting a 39.0% year-over-year increase, showcasing the company's growth potential in the market despite the downward revisions in EPS expectations.
- Revision Trends Analysis: Over the past three months, there have been no upward revisions in EPS estimates, with one downward revision, while revenue estimates have seen three downward adjustments, indicating a cautious market outlook on the company's future performance.
See More
